Please login to the form below

Not currently logged in
Email:
Password:

RotaTeq

This page shows the latest RotaTeq news and features for those working in and with pharma, biotech and healthcare.

Sanofi unit takes low-cost rotavirus vaccine into phase III

Sanofi unit takes low-cost rotavirus vaccine into phase III

and Merck &Co's RotaTeq which, while effective, are still unaffordable for many countries battling with the infection. ... III trials, promising to make it available at around one-tenth the price of Rotarix and RotaTeq.

Latest news

  • GSK's Rotarix vaccine resumes use in US

    They suggested doctors use Merck's RotaTeq vaccine instead. . On Friday (May 14, 2010), the agency reversed its decision, saying there is no evidence that porcine circovirus can infect or sicken

  • Virus found in GSK's Rotarix vaccine

    Preliminary testing on Merck's RotaTeq, another rotavirus vaccine, has found no traces of PCV1.

  • WHO recommends rotavirus vaccines

    Data on Merck's rotavirus vaccine, RotaTeq, from clinical trials in Bangladesh, Vietnam, Ghana, Mali, and Kenya are expected in the autumn.

  • GSK's Rotarix protects against commonest rotaviruses

    The company has already obtained EU marketing approval. However, Merck &Co's RotaTeq was approved in the US in February 2007, and an advisory committee of the US Centers for Disease ... Control and Prevention (CDC) recently voted to recommend that all

  • Pharma news in brief

    Last month, Merck's rival Rotateq vaccine gained US Food and Drug Administration (FDA) approval as well as a Centers for Disease Control recommendation that it would be reimbursable by the

More from news
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics